NVCT vs RVMD
NVCT: Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including breast, lung, prostate, and pancreatic cancers. RVMD: A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
Side-by-side fundamentals
| Metric | NVCT | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.29 | $183.03 | |
| Market cap as of 2026-07-23 | $608M | $39.0B | |
| PEG as of 2026-07-23 | -0.89 | -0.34 | NVCT lower |
| Net margin as of 2026-07-23 | n/a | -2833.9% | |
| Operating margin as of 2026-07-23 | n/a | -3145.0% | |
| ROE as of 2026-07-23 | -147.8% | -54.1% | RVMD higher |
| ROA as of 2026-07-23 | -90.8% | -39.1% | RVMD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.19 | NVCT lower |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | -0.24 | 1.41 | |
| 1-year return as of 2026-07-22 close | +139.1% | +378.3% | RVMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.